Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Gilead Sciences stock nears its all-time high
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 5,634.58 and the Dow Jones Industrial Average DJIA falling 0.04% to 41,606.18.
Gilead Sciences stock nears its all-time high: buy or sell?
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million settlement with American authorities. It has risen for two consecutive weeks,
ENDPOINTS NEWS
2h
Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles
Gilead Science’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the ...
FiercePharma
16h
Gilead's Kite exits China cell therapy joint venture with Fosun Pharma
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
Korea Joongang Daily on MSN
12h
Yuhan inks $80.9 million deal with Gilead Sciences for HIV ingredients
Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...
7d
on MSN
Gilead’s HIV Shot Reduced Infections By 96% In Late-Stage Trial—Beating Daily Pill
Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...
6d
Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says
Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...
BioSpace
7d
Gilead Touts 96% HIV Risk Reduction With Twice-Yearly PrEP, Eyes Regulatory Filings
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
FierceBiotech
9d
Gilead inks $35M collab with AI drug discovery outfit Genesis
Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences. | ...
4d
Hold Rating on Gilead Sciences Amid Lenacapavir’s Promise and Market Uncertainties
Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
HIV
S&P 500 Index
lenacapavir
Feedback